The Sclerosing Cholangitis Outcomes in Pediatrics (SCOPE) Index: A Prognostic Tool for Children

Mark R. Deneau, Cara Mack, Emily R. Perito, Amanda Ricciuto, Pamela L. Valentino, Mansi Amin, Achiya Z. Amir, Madeleine Aumar, Marcus Auth, Annemarie Broderick, Matthew DiGuglielmo, Laura G. Draijer, Eleonora Druve Tavares Fagundes, Wael El-Matary, Federica Ferrari, Katryn N. Furuya, Nitika Gupta, Jessica T. Hochberg, Matjaz Homan, Simon HorslenRaffaele Iorio, M. Kyle Jensen, Maureen M. Jonas, Binita M. Kamath, Nanda Kerkar, Kyung Mo Kim, Kaija Leena Kolho, Bart G.P. Koot, Trevor J. Laborda, Christine K. Lee, Kathleen M. Loomes, Mercedes Martinez, Alexander Miethke, Tamir Miloh, Douglas Mogul, Saeed Mohammad, Parvathi Mohan, Stacy Moroz, Nadia Ovchinsky, Sirish Palle, Alexandra Papadopoulou, Girish Rao, Alexandre Rodrigues Ferreira, Pushpa Sathya, Kathleen B. Schwarz, Uzma Shah, Eyal Shteyer, Ruchi Singh, Vratislav Smolka, Nisreen Soufi, Atsushi Tanaka, Raghu Varier, Bernadette Vitola, Marek Woynarowski, Melissa Zerofsky, Andréanne Zizzo, Stephen L. Guthery

Research output: Contribution to journalArticlepeer-review

20 Scopus citations


Background and Aims: Disease progression in children with primary sclerosing cholangitis (PSC) is variable. Prognostic and risk-stratification tools exist for adult-onset PSC, but not for children. We aimed to create a tool that accounts for the biochemical and phenotypic features and early disease stage of pediatric PSC. Approach and Results: We used retrospective data from the Pediatric PSC Consortium. The training cohort contained 1,012 patients from 40 centers. We generated a multivariate risk index (Sclerosing Cholangitis Outcomes in Pediatrics [SCOPE] index) that contained total bilirubin, albumin, platelet count, gamma glutamyltransferase, and cholangiography to predict a primary outcome of liver transplantation or death (TD) and a broader secondary outcome that included portal hypertensive, biliary, and cancer complications termed hepatobiliary complications (HBCs). The model stratified patients as low, medium, or high risk based on progression to TD at rates of <1%, 3%, and 9% annually and to HBCs at rates of 2%, 6%, and 13% annually, respectively (P < 0.001). C-statistics to discriminate outcomes at 1 and 5 years were 0.95 and 0.82 for TD and 0.80 and 0.76 for HBCs, respectively. Baseline hepatic fibrosis stage was worse with increasing risk score, with extensive fibrosis in 8% of the lowest versus 100% with the highest risk index (P < 0.001). The model was validated in 240 children from 11 additional centers and performed well. Conclusions: The SCOPE index is a pediatric-specific prognostic tool for PSC. It uses routinely obtained, objective data to predict a complicated clinical course. It correlates strongly with biopsy-proven liver fibrosis. SCOPE can be used with families for shared decision making on clinical care based on a patient’s individual risk, and to account for variable disease progression when designing future clinical trials.

Original languageEnglish (US)
Pages (from-to)1074-1087
Number of pages14
Issue number3
StatePublished - Mar 2021

ASJC Scopus subject areas

  • Hepatology


Dive into the research topics of 'The Sclerosing Cholangitis Outcomes in Pediatrics (SCOPE) Index: A Prognostic Tool for Children'. Together they form a unique fingerprint.

Cite this